BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsGlobeNewsWire • Wednesday
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024GlobeNewsWire • 03/20/24
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyGlobeNewsWire • 03/12/24
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart FailureGlobeNewsWire • 03/04/24
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDAGlobeNewsWire • 02/08/24
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics ConferenceGlobeNewsWire • 01/31/24
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for ShareholdersGlobeNewsWire • 01/03/24
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection FractionGlobeNewsWire • 12/19/23
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesGlobeNewsWire • 12/18/23
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product ApprovalGlobeNewsWire • 11/29/23
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 11/16/23
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart FailureGlobeNewsWire • 11/14/23
BioCardia Reports Third Quarter 2023 Business Highlights and Financial ResultsGlobeNewsWire • 11/08/23
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023GlobeNewsWire • 11/01/23
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial IIGlobeNewsWire • 10/11/23
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy ProgramsGlobeNewsWire • 09/06/23
BioCardia shares slide on disappointing interim data from heart therapy trialProactive Investors • 09/05/23
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure TrialGlobeNewsWire • 09/05/23